- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04797442
Effect of Akkermansia Muciniphila WST01 Strain in Overweight or Obese Patients With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Effect of Akkermansia Muciniphila WST01 Strain in Patients With Type 2 Diabetes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In the present study, about 60 overweight/obese and drug naïve type 2 diabetes patients will be enrolled from multiple centers in China. After screening, eligible subjects will be randomized (1:1) into two groups, taking either Akkermansia muciniphila WST01 strain product or placebo product for 12 weeks.
Blood, feces and urine samples will be collected before and after treatment. Metabolic parameters including waist and hip circumference, area of visceral and subcutaneous fat, glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), insulin, glucagon-like peptide 1 (GLP-1), inflammation factors and lipid levels will be measured. Furthermore, the change of gut microbiota and metabolites will be evaluated too.
The primary objective is to determine whether Akkermansia muciniphila WST01 strain has a positive effect in patients with Type 2 Diabetes. The secondary objective is to explore the effect of Akkermansia muciniphila WST01 strain on safety, intestinal flora, insulin sensitivity, and other metabolic indicators and metabolites in the patients.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200025
- Dep.endocrinology of Shanghai Ruijin Hospital, Shanghai Jiaotong university school of medcine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Main Inclusion Criteria:
- Subjects with type 2 diabetes mellitus;
- Age 18-60 years;
- Overweight / obesity (24.0 ≤ BMI ≤ 40.0 kg/m2);
- Subjects with or without other obesity related metabolic complications (hypertension, dyslipidemia, hyperuricemia, etc.);
- Subjects with screening HbA1c ≥ 7.0% and ≤ 10.0%, and the fasting blood glucose ≥ 7.0 mmol/l and ≤ 13.3 mmol/l;
- Subjects who are not taking any medications to control blood glucose;
- Subjects control blood glucose only by lifestyle intervention (diet and exercise) for at least 2 months before the screening period;
- Subjects understand the nature, significance, potential benefits, inconvenience, and risks of the study before it starts;
- Subjects fully understand the study produces and voluntarily sign the informed consent form.
Main Exclusion Criteria:
- Subjects with a history of taking hypoglycemic drugs;
- Subjects who are pregnant or in lactation;
- Subjects with type 1 diabetes, single gene mutation diabetes, diabetes due to pancreatic injury or other secondary diabetes (such as Cushing's syndrome, thyroid dysfunction or acromegaly, etc.);
- Subjects who were or are using oral hypoglycemic agents or insulin or incretin to control diabetes;
- Subjects with liver and kidney dysfunction (alanine transaminase(ALT) / aspartate aminotransferase(AST)≥2.5×the upper limit of normal(ULN) set by the hospital, serum creatinine>1×ULN set by the hospital, or eGFR<60mL/min/1.73m2);
- Surgery with serious cardiovascular and cerebrovascular diseases (such as heart failure, myocardial infarction, cerebral infarction, acute myocarditis, severe arrhythmia, patients receiving interventional therapy, etc.) or stage III hypertension (systolic blood pressure cannot be controlled below 160 mmHg with three antihypertensive drugs);
- Subjects with acute diabetic complications such as diabetic ketoacidosis or diabetic hyperosmolar coma in the past 3 months;
- Subjects with a medical history of malignant tumor (except local skin basal cell carcinoma) in the past 5 years;
- Subjects with a medical history of intestine, or other digestive tract surgery (such as cholecystectomy) within one year, or other non-gastrointestinal surgery within 6 months;
- Any condition that in the judgement of the investigator precludes participation.
Details please see the study protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental
|
orally given WST01 strain product, added onto lifestyle.
The specific ingredients are the optimized Akkermansia muciniphila WST01 strain powder with maximum live bacteria of 5*10^10 CFU/g (1 g/pack, 3 packs QD, 20-30 min after breakfast)
|
Placebo Comparator: Placebo comparator
|
orally given placebo powder (the specific ingrdients are the excipients of the WST01 strain powder), added onto lifestyle.
(3 packs of placebo powder QD, 20-30 min after breakfast)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Body weight
Time Frame: 12 weeks
|
change of body weight from baseline
|
12 weeks
|
Fasting plasma glucose levels
Time Frame: 12 weeks
|
change of fasting plasma glucose from baseline
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gut microbiome
Time Frame: 12 weeks
|
including fecal intestinal flora metagenome
|
12 weeks
|
Glycated haemoglobin (HbA1c)
Time Frame: 12 weeks
|
12 weeks
|
|
2-hour post-prandial plasma glucose levels
Time Frame: 12 weeks
|
12 weeks
|
|
Fasting serum insulin levels
Time Frame: 12 weeks
|
12 weeks
|
|
2-hour post-prandial serum insulin levels
Time Frame: 12 weeks
|
12 weeks
|
|
Fasting glucagon-like peptide-1 (GLP-1) levels
Time Frame: 12 weeks
|
12 weeks
|
|
2-hour post-prandial GLP-1 levels
Time Frame: 12 weeks
|
12 weeks
|
|
Serum triglycerides
Time Frame: 12 weeks
|
12 weeks
|
|
Serum total cholesterol
Time Frame: 12 weeks
|
12 weeks
|
|
Serum LDL-c
Time Frame: 12 weeks
|
12 weeks
|
|
Serum HDL-c
Time Frame: 12 weeks
|
12 weeks
|
|
Area of visceral and subcutaneous fat
Time Frame: 12 weeks
|
12 weeks
|
|
Waist and hip circumference
Time Frame: 12 weeks
|
12 weeks
|
|
Energy expenditure
Time Frame: 12 weeks
|
using metabolic chamber to measure energy expenditure
|
12 weeks
|
Blood metabolomics profile measurement
Time Frame: 12 weeks
|
In aid of LC/MS and GC/MS technique, etc, we will measure the metabolomics molecular profile in blood samples before and after treatment.
The metabolomics measurement will help to detect the profile of all kinds of bile acid species, lipids species and amino acid species, etc.
The composition change of all these biological molecular induced by the treatment is our major interest rather than single molecular quantification.
|
12 weeks
|
Inflammation markers
Time Frame: 12 weeks
|
including hs-CRP, TNF-alfa, IL-6, and IL-8, etc
|
12 weeks
|
Systolic and diastolic blood pressure
Time Frame: 12 weeks
|
Safety outcomes
|
12 weeks
|
Body temperature
Time Frame: 12 weeks
|
Safety outcomes
|
12 weeks
|
Pulse rate
Time Frame: 12 weeks
|
Safety outcomes
|
12 weeks
|
White blood cell (WBC) count
Time Frame: 12 weeks
|
Safety outcomes
|
12 weeks
|
Red blood cell (RBC) count
Time Frame: 12 weeks
|
Safety outcomes
|
12 weeks
|
Hemoglobin levels
Time Frame: 12 weeks
|
Safety outcomes
|
12 weeks
|
Platelet count
Time Frame: 12 weeks
|
Safety outcomes
|
12 weeks
|
Hepatic function
Time Frame: 12 weeks
|
including alanine aminotransferase, aspartate aminotransferase,ɣ-glutamyltransferase, and alkaline phosphatase
|
12 weeks
|
Renal function
Time Frame: 12 weeks
|
including serum urea nitrogen, serum creatinine, and serum urinary acid
|
12 weeks
|
Adverse events
Time Frame: 12 weeks
|
Safety outcomes
|
12 weeks
|
Fasting serum C peptide levels
Time Frame: 12 weeks
|
12 weeks
|
|
2-hour post-prandial serum C peptide levels
Time Frame: 12 weeks
|
12 weeks
|
|
Lean mass
Time Frame: 12 weeks
|
using DEXA scan to measure lean mass
|
12 weeks
|
Fat mass
Time Frame: 12 weeks
|
using DEXA scan to measure fat mass
|
12 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WST001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overweight
-
University Hospital, LilleNational Research Agency, France; European Union; University of Lille Nord de... and other collaboratorsNot yet recruitingOverweight and Obesity | Overweight, Childhood | Overweight, Infant
-
Children's Hospital Los AngelesUniversity of Southern California; Tufts Medical CenterRecruitingOverweight and Obesity | Overweight AdolescentsUnited States
-
University of AarhusThe Danish Dairy Research Foundation, Denmark; Sygekassernes HelsefondCompletedOverweight and Obesity | Overweight Adolescents | Metabolic DiseaseDenmark
-
Memorial Sloan Kettering Cancer CenterRecruitingObesity | Overweight | Overweight and Obesity | Obese | Overweight or ObesityUnited States
-
University Hospital Bispebjerg and FrederiksbergUniversity of CopenhagenCompleted
-
Holbaek SygehusUniversity of Copenhagen; University of Florida; University of Minnesota; Hebrew... and other collaboratorsRecruitingChildhood Overweight and ObesityDenmark
-
Khyber Medical University PeshawarRecruitingObesity, OverweightPakistan
-
National Taiwan University HospitalCompleted
-
Institut Investigacio Sanitaria Pere VirgiliCompletedObesity, Childhood | Overweight and Obesity | Overweight, ChildhoodSpain
-
Children's Hospital SrebrnjakBelupo; Podravka d.d.RecruitingBody Weight | Overweight and ObesityCroatia
Clinical Trials on WST01 strain product
-
Johns Hopkins Bloomberg School of Public HealthUnited States Department of Defense; Naval Medical Research CenterActive, not recruiting
-
Universidad Autonoma de San Luis PotosíCompletedChildhood Obesity | Childhood OverweightMexico
-
Johns Hopkins Bloomberg School of Public HealthUnited States Department of Defense; Naval Medical Research CenterCompleted
-
Long Island UniversityTerminatedOther Instability, Ankle and FootUnited States
-
Riphah International UniversityCompletedTrigger Point Pain, MyofascialPakistan
-
Cairo UniversityKing Khalid UniversityCompletedLower Back Myofascial Pain SyndromeSaudi Arabia
-
Riphah International UniversityCompleted
-
Brigham Young UniversityCompletedTrigger Point Pain, MyofascialUnited States
-
Centre Hospitalier Universitaire de NīmesCompletedUltrasound Strain MeasurementFrance
-
Simon AnnaheimCompletedHeat StressSwitzerland